文献速递免疫规划传染病防控与疫情报告

弓形虫SAG1 mRNA疫苗的构建及其对小鼠急性弓形虫病的免疫保护效果

Design and synthesis of RNA vaccines encoding SAG1 antigen of toxoplasma gondii and evaluation of immunogenicity and its protective efficacy against acute toxoplasmosis in BALB/c mice.
PubMed 文献 · Vaccine · 2026-06-11

本研究设计并合成了编码弓形虫SAG1抗原的mRNA疫苗,在BALB/c小鼠中评估其免疫原性及对急性弓形虫病的保护效果。结果显示SAG1 mRNA疫苗诱导了较强的细胞和体液免疫应答,且抗急性感染保护作用显著优于SAG1 DNA疫苗。

要点

  • SAG1 mRNA疫苗可诱导体液和细胞免疫,以Th1型应答为主。
  • SAG1 mRNA疫苗抗急性感染保护作用优于SAG1 DNA疫苗。
  • 接种后未检测到肝细胞明显炎症或形态学改变。

核心结论

  • 基于mRNA平台递送SAG1抗原可能为弓形虫疫苗开发提供可行策略,值得进一步研究。

研究设计与样本

  • 设计编码弓形虫SAG1基因的RNA疫苗,体外验证蛋白表达后经肌内注射免疫BALB/c小鼠,评估免疫应答与保护效果。

主要发现

  • SAG1 mRNA免疫小鼠诱导了细胞和体液免疫应答,弓形虫特异性IgG抗体滴度升高(P < 0.01),以IgG2a亚类为主。
  • 细胞因子分析显示IFN-γ和IL-4水平升高(P < 0.05),呈混合Th1/Th2应答且以Th1活性为主。
  • 免疫后TNF-α、IL-1和IL-6三种关键炎症介质表达水平显著升高(P < 0.01)。
  • 接种后未检测到肝细胞明显炎症或形态学改变。
  • 免疫小鼠的死亡率和寄生虫负荷发生显著变化(P < 0.001),且对急性感染的保护作用显著优于SAG1 DNA疫苗组。

临床怎么用

  • 提示mRNA平台可用于弓形虫疫苗候选抗原SAG1的递送,支持后续疫苗开发研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Toxoplasmosis represents a significant global health concern due to the limited availability of safe and effective vaccines and drugs. mRNA technology offers a promising approach for toxoplasmosis vaccine development, combining effectiveness with enhanced safety features. Unlike DNA vaccines, mRNA vaccines remain exclusively in the cytoplasm, eliminating the risk of genomic integration and malignant cell transformation. We designed an RNA-based vaccine encoding the T. gondii SAG1 gene and validated its protein expression in vitro using Western blotting and indirect fluorescent antibody testing (IFAT). Following intramuscular administration in BALB/c mice, we evaluated the resulting protective immune responses. Mice immunized with SAG1 mRNA exhibited robust immune responses involving both cellular and humoral immunity. Immunological analysis revealed elevated titers of T. gondii-specific IgG antibodies (P < 0.01), with predominant representation of the IgG2a subclass relative to IgG1. Cytokine analysis revealed elevation of IFN-γ and IL-4 levels (P < 0.05), indicating a mixed Th1/Th2 immune response with predominant Th1 activity. Following SAG1 mRNA immunization, there was a marked increase in the expression levels of three key inflammatory mediators: tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) (P < 0.01). No significant inflammatory or morphological changes were detected in hepatocytes post-vaccination. This immunological response was associated with significant alterations in mortality rates and parasite burdens in vaccinated mice (P < 0.001). Most importantly, mice vaccinated with SAG1 mRNA showed significantly enhanced protection against acute infection compared to those receiving the SAG1 DNA vaccine. Our findings suggest that the use of an mRNA-based platform for SAG1 delivery may provide a feasible strategy for vaccine development against T. gondii, supporting further investigation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zaki L, Ghaffarifar F, Sharifi Z, et al. Design and synthesis of RNA vaccines encoding SAG1 antigen of toxoplasma gondii and evaluation of immunogenicity and its protective efficacy against acute toxoplasmosis in BALB/c mice. Vaccine. 2026. PMID: 42275801. doi:10.1016/j.vaccine.2026.128785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。